Zenara Pharma launches generic of Pfizer Paxlovid at Rs 5,200 per box in India

Published On 2022-09-11 09:03 GMT   |   Update On 2022-12-07 11:28 GMT

Hyderabad-based Zenara Pharma, a fully owned subsidiary of Biophore India Pharmaceuticals, has announced that the company has launched Nirmatrelvir and Ritonavir tablets in a combi pack as a treatment option for patients with mild to moderate symptoms of Covid-19.It is to be noted that Zenara Pharma has received approval from the Central Drugs Standard Control Organization (CDSCO) to...

Login or Register to read the full article
Hyderabad-based Zenara Pharma, a fully owned subsidiary of Biophore India Pharmaceuticals, has announced that the company has launched Nirmatrelvir and Ritonavir tablets in a combi pack as a treatment option for patients with mild to moderate symptoms of Covid-19.

It is to be noted that Zenara Pharma has received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market this product last month. The tablet, which will be sold under the brand name 'Paxzen', is being manufactured at Zenara's USFDA and EU approved state-of-the-art facility in Hyderabad.

For more details, check out the link given below:
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News